IMMUTEP LTD ORDINARY (IMM) Short Interest
IMMUTEP LTD ORDINARY (ASX:IMM) had 2.39% of shares reported as short positions as of 16 July 2026, representing 35,229,148 shares. IMMUTEP LTD ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Immutep
Immutep is a biotechnology company focused on developing LAG-3 related immunotherapy products for the treatment of cancer and autoimmune diseases. The company is pioneering the LAG-3 space and has clinical-stage assets targeting areas of high unmet need.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4IMM intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Immutep
Latest IMM news
All news- Fourth U.S. Patent Secured for Efti and PD-1 Combination
asx
- Immutep (ASX:IMM) Shares Surge Nearly 14% as Healthcare Momentum Grabs the ASX Spotlight - Kalkine
googlenews
- Health Check: Immutep shares bounce on revived lung cancer treatment hopes
stockhead
- TACTI-004 Update & Positive Mature Data from INSIGHT-003
asx
- Ceasing to be a substantial holder
asx
About
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss IMM
Start a research thread or post the first pulse update